Cargando…

Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinoma—a systematic review and meta-analysis

INTRODUCTION: The 12-gene recurrence score (RS) is a clinically validated assay which predicts recurrence risk in patients with stage II/III colon cancer. Decisions regarding adjuvant chemotherapy may be guided using this assay or based on the judgement of tumour board. AIMS: To assess the concordan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davey, Matthew G., O’Neill, Maeve, Regan, Mark, Meshkat, Babak, Nugent, Emmeline, Joyce, Myles, Hogan, Aisling M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011316/ https://www.ncbi.nlm.nih.gov/pubmed/36912973 http://dx.doi.org/10.1007/s00384-023-04364-2

Ejemplares similares

Evaluating the oncological safety of neoadjuvant chemotherapy in locally advanced colon carcinoma: a systematic review and meta-analysis of randomised clinical trials and propensity-matched studies
por: Davey, Matthew G., et al.
Publicado: (2023)

Immunoscore in mismatch repair‐proficient and ‐deficient colon cancer
por: Wirta, Erkki‐Ville, et al.
Publicado: (2017)

Riding the waves: the ongoing impact of COVID-19 on a national surgical training cohort
por: Hennessy, Orla, et al.
Publicado: (2021)

Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer
por: Jimenez-Rodriguez, Rosa M., et al.
Publicado: (2020)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
por: Zhu, Jiangpeng, et al.
Publicado: (2023)

Adrenaline auto-injector prescription and patients’ administration proficiency
por: Amaral, Luis, et al.
Publicado: (2015)

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002)

Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2022)

Neoadjuvant radiotherapy for rectal cancer management
por: Feeney, Gerard, et al.
Publicado: (2019)

A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer
por: Yarchoan, Mark, et al.
Publicado: (2019)

Extramedullary Hematopoiesis in Mismatch Repair Deficient Colon Cancer Patient on Adjuvant Chemotherapy
por: De Leo, Edward K, et al.
Publicado: (2021)

Robust Glycogene-Based Prognostic Signature for Proficient Mismatch Repair Colorectal Adenocarcinoma
por: Li, Yixi, et al.
Publicado: (2021)

Risk for Hereditary Neoplastic Syndromes in Women with Mismatch Repair-Proficient Endometrial Cancer
por: dos Santos, Jennifer Thalita Targino, et al.
Publicado: (2023)

Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes
por: Kim, Jin K., et al.
Publicado: (2022)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
por: Tomasello, Gianluca, et al.
Publicado: (2022)

Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer
por: Eppenberger, Manuela, et al.
Publicado: (2010)

Characterisation of the oxysterol metabolising enzyme pathway in mismatch repair proficient and deficient colorectal cancer
por: Swan, Rebecca, et al.
Publicado: (2016)

Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma
por: Giacomelli, Mauro, et al.
Publicado: (2023)

Comprehensive Analysis of Differentially Expressed Long Noncoding RNA-mRNA in the Adenoma-Carcinoma Sequence of DNA Mismatch Repair Proficient Colon Cancer
por: Li, Wenkun, et al.
Publicado: (2021)

ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
por: Li, P, et al.
Publicado: (2013)

Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
por: Nehmé, A, et al.
Publicado: (1999)

Comparison of immunological characteristics between paired mismatch repair-proficient and -deficient colorectal cancer patients
por: Liu, Shou-Sheng, et al.
Publicado: (2018)

Distinct microbes, metabolites, and ecologies define the microbiome in deficient and proficient mismatch repair colorectal cancers
por: Hale, Vanessa L., et al.
Publicado: (2018)

Efficient engineering of chromosomal ribosome binding site libraries in mismatch repair proficient Escherichia coli
por: Oesterle, Sabine, et al.
Publicado: (2017)

Awareness and Uptake of Family Screening in Patients Diagnosed with Colorectal Cancer at a Young Age
por: Hogan, Niamh M., et al.
Publicado: (2015)

Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2023)

IGSF6 is a novel biomarker to evaluate immune infiltration in mismatch repair-proficient colorectal cancer
por: Rong, Yu-ming, et al.
Publicado: (2023)

Progress towards an inducible, replication-proficient transposon delivery vector for Chlamydia trachomatis
por: Skilton, Rachel J., et al.
Publicado: (2021)

Combination of primary tumor location and mismatch repair status guides adjuvant chemotherapy in stage II colon cancer
por: Yang, Lin, et al.
Publicado: (2017)

Microsatellite stability and mismatch repair proficiency in nasopharyngeal carcinoma may not predict programmed death-1 blockade resistance
por: Liao, Xiyi, et al.
Publicado: (2017)

Surprising trunk rotational capabilities in chimpanzees and implications for bipedal walking proficiency in early hominins
por: Thompson, Nathan E., et al.
Publicado: (2015)

Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
por: Lau, David, et al.
Publicado: (2020)

BRD4 inhibition impairs DNA mismatch repair, induces mismatch repair mutation signatures and creates therapeutic vulnerability to immune checkpoint blockade in MMR-proficient tumors
por: Fu, Yu, et al.
Publicado: (2023)

Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort
por: Zwart, Koen, et al.
Publicado: (2023)

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
por: Taieb, J., et al.
Publicado: (2019)

When There is No Guidance From the Guidelines: Renal Transplantation in Recipients With Class III Obesity
por: Gillespie, Hannah, et al.
Publicado: (2023)

Success of patient training in improving proficiency of eyedrop administration among various ophthalmic patient populations
por: Feng, Alexander, et al.
Publicado: (2016)

Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
por: Zhou, Guoying, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bo4g87e5qp0ssri28f06hg4mmr